Korean Journal of Radiology

The Korean Society of Radiology (대한영상의학회)
권호 표지
DOI QR코드

DOI QR Code

A Comparison of Substantia Nigra T1 Hyperintensity in Parkinson's Disease Dementia, Alzheimer's Disease and Age-Matched Controls: Volumetric Analysis of Neuromelanin Imaging

  • Moon, Won-Jin (Department of Radiology, Konkuk University School of Medicine) ;
  • Park, Ju-Yeon (Department of Radiology, Konkuk University School of Medicine) ;
  • Yun, Won-Sung (Department of Radiology, Konkuk University School of Medicine) ;
  • Jeon, Ji Yeong (Department of Radiology, Konkuk University School of Medicine) ;
  • Moon, Yeon Sil (Department of Neurology, Konkuk University School of Medicine) ;
  • Kim, Heejin (Department of Neurology, Konkuk University School of Medicine) ;
  • Kwak, Ki-Chang (Department of Biomedical Engineering, Hanyang University) ;
  • Lee, Jong-Min (Department of Biomedical Engineering, Hanyang University) ;
  • Han, Seol-Heui (Department of Neurology, Konkuk University School of Medicine)
  • Received : 2015.12.01
  • Accepted : 2016.04.27
  • Published : 2016.09.01
⟨ Previous Next ⟩

Abstract

Objective: Neuromelanin loss of substantia nigra (SN) can be visualized as a T1 signal reduction on T1-weighted high-resolution imaging. We investigated whether volumetric analysis of T1 hyperintensity for SN could be used to differentiate between Parkinson's disease dementia (PDD), Alzheimer's disease (AD) and age-matched controls. Materials and Methods: This retrospective study enrolled 10 patients with PDD, 18 patients with AD, and 13 age-matched healthy elderly controls. MR imaging was performed at 3 tesla. To measure the T1 hyperintense area of SN, we obtained an axial thin section high-resolution T1-weighted fast spin echo sequence. The volumes of interest for the T1 hyperintense SN were drawn onto heavily T1-weighted FSE sequences through midbrain level, using the MIPAV software. The measurement differences were tested using the Kruskal-Wallis test followed by a post hoc comparison. Results: A comparison of the three groups showed significant differences in terms of volume of T1 hyperintensity (p < 0.001, Bonferroni corrected). The volume of T1 hyperintensity was significantly lower in PDD than in AD and normal controls (p < 0.005, Bonferroni corrected). However, the volume of T1 hyperintensity was not different between AD and normal controls (p = 0.136, Bonferroni corrected). Conclusion: The volumetric measurement of the T1 hyperintensity of SN can be an imaging marker for evaluating neuromelanin loss in neurodegenerative diseases and a differential in PDD and AD cases.

Keywords

Acknowledgement

Supported by : Ministry of Health & Welfare

References

  1. Zecca L, Tampellini D, Gerlach M, Riederer P, Fariello RG, Sulzer D. Substantia nigra neuromelanin: structure, synthesis, and molecular behaviour. Mol Pathol 2001;54:414-418
  2. Double KL, Ben-Shachar D, Youdim MB, Zecca L, Riederer P, Gerlach M. Influence of neuromelanin on oxidative pathways within the human substantia nigra. Neurotoxicol Teratol 2002;24:621-628 https://doi.org/10.1016/S0892-0362(02)00218-0
  3. Zecca L, Zucca FA, Wilms H, Sulzer D. Neuromelanin of the substantia nigra: a neuronal black hole with protective and toxic characteristics. Trends Neurosci 2003;26:578-580 https://doi.org/10.1016/j.tins.2003.08.009
  4. Sasaki M, Shibata E, Tohyama K, Takahashi J, Otsuka K, Tsuchiya K, et al. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease. Neuroreport 2006;17:1215-1218 https://doi.org/10.1097/01.wnr.0000227984.84927.a7
  5. Sasaki M, Shibata E, Tohyama K, Kudo K, Endoh J, Otsuka K, et al. Monoamine neurons in the human brain stem: anatomy, magnetic resonance imaging findings, and clinical implications. Neuroreport 2008;19:1649-1654 https://doi.org/10.1097/WNR.0b013e328315a637
  6. Matsuura K, Maeda M, Yata K, Ichiba Y, Yamaguchi T, Kanamaru K, et al. Neuromelanin magnetic resonance imaging in Parkinson's disease and multiple system atrophy. Eur Neurol 2013;70:70-77 https://doi.org/10.1159/000350291
  7. Ohtsuka C, Sasaki M, Konno K, Kato K, Takahashi J, Yamashita F, et al. Differentiation of early-stage parkinsonisms using neuromelanin-sensitive magnetic resonance imaging. Parkinsonism Relat Disord 2014;20:755-760 https://doi.org/10.1016/j.parkreldis.2014.04.005
  8. Kashihara K, Shinya T, Higaki F. Reduction of neuromelanin-positive nigral volume in patients with MSA, PSP and CBD. Intern Med 2011;50:1683-1687 https://doi.org/10.2169/internalmedicine.50.5101
  9. Shibata E, Sasaki M, Tohyama K, Otsuka K, Endoh J, Terayama Y, et al. Use of neuromelanin-sensitive MRI to distinguish schizophrenic and depressive patients and healthy individuals based on signal alterations in the substantia nigra and locus ceruleus. Biol Psychiatry 2008;64:401-406 https://doi.org/10.1016/j.biopsych.2008.03.021
  10. Song IU, Kim JS, Yoo JY, Song HJ, Lee KS. Cognitive dysfunctions in mild Parkinson's disease dementia: comparison with patients having mild Alzheimer's disease and normal controls. Eur Neurol 2008;59:49-54 https://doi.org/10.1159/000109261
  11. Song IU, Chung YA, Chung SW, Jeong J. Early diagnosis of Alzheimer's disease and Parkinson's disease associated with dementia using cerebral perfusion SPECT. Dement Geriatr Cogn Disord 2014;37:276-285 https://doi.org/10.1159/000357128
  12. Martorana A, Koch G. “Is dopamine involved in Alzheimer's disease?”. Front Aging Neurosci 2014;6:252
  13. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184 https://doi.org/10.1136/jnnp.55.3.181
  14. Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007;22:1689-1707; quiz 1837 https://doi.org/10.1002/mds.21507
  15. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944 https://doi.org/10.1212/WNL.34.7.939
  16. Kitao S, Matsusue E, Fujii S, Miyoshi F, Kaminou T, Kato S, et al. Correlation between pathology and neuromelanin MR imaging in Parkinson's disease and dementia with Lewy bodies. Neuroradiology 2013;55:947-953 https://doi.org/10.1007/s00234-013-1199-9
  17. Kashihara K, Shinya T, Higaki F. Neuromelanin magnetic resonance imaging of nigral volume loss in patients with Parkinson's disease. J Clin Neurosci 2011;18:1093-1096 https://doi.org/10.1016/j.jocn.2010.08.043
  18. Schwarz ST, Rittman T, Gontu V, Morgan PS, Bajaj N, Auer DP. T1-weighted MRI shows stage-dependent substantia nigra signal loss in Parkinson's disease. Mov Disord 2011;26:1633-1638 https://doi.org/10.1002/mds.23722
  19. Miyoshi F, Ogawa T, Kitao SI, Kitayama M, Shinohara Y, Takasugi M, et al. Evaluation of Parkinson disease and Alzheimer disease with the use of neuromelanin MR imaging and (123)I-metaiodobenzylguanidine scintigraphy. AJNR Am J Neuroradiol 2013;34:2113-2118 https://doi.org/10.3174/ajnr.A3567
  20. Ogisu K, Kudo K, Sasaki M, Sakushima K, Yabe I, Sasaki H, et al. 3D neuromelanin-sensitive magnetic resonance imaging with semi-automated volume measurement of the substantia nigra pars compacta for diagnosis of Parkinson's disease. Neuroradiology 2013;55:719-724 https://doi.org/10.1007/s00234-013-1171-8
  21. Sasaki M, Shibata E, Kudo K, Tohyama K. Neuromelanin-sensitive MRI: basics, technique, and clinical applications. Clin Neuroradiol 2008;18:147-153 https://doi.org/10.1007/s00062-008-8018-4
  22. Tosk JM, Holshouser BA, Aloia RC, Hinshaw DB Jr, Hasso AN, MacMurray JP, et al. Effects of the interaction between ferric iron and L-dopa melanin on T1 and T2 relaxation times determined by magnetic resonance imaging. Magn Reson Med 1992;26:40-45 https://doi.org/10.1002/mrm.1910260105
  23. Melki PS, Mulkern RV. Magnetization transfer effects in multislice RARE sequences. Magn Reson Med 1992;24:189-195 https://doi.org/10.1002/mrm.1910240122
  24. Lehericy S, Bardinet E, Poupon C, Vidailhet M, Francois C. 7 Tesla magnetic resonance imaging: a closer look at substantia nigra anatomy in Parkinson's disease. Mov Disord 2014;29:1574-1581 https://doi.org/10.1002/mds.26043
  25. Zecca L, Casella L, Albertini A, Bellei C, Zucca FA, Engelen M, et al. Neuromelanin can protect against iron-mediated oxidative damage in system modeling iron overload of brain aging and Parkinson's disease. J Neurochem 2008;106:1866-1875
  26. Kashihara K, Hanaoka A, Imamura T. Frequency and characteristics of taste impairment in patients with Parkinson's disease: results of a clinical interview. Intern Med 2011;50:2311-2315 https://doi.org/10.2169/internalmedicine.50.5935
  27. Cosottini M, Frosini D, Pesaresi I, Costagli M, Biagi L, Ceravolo R, et al. MR imaging of the substantia nigra at 7 T enables diagnosis of Parkinson disease. Radiology 2014;271:831-838 https://doi.org/10.1148/radiol.14131448
  28. Kwon DH, Kim JM, Oh SH, Jeong HJ, Park SY, Oh ES, et al. Seven-Tesla magnetic resonance images of the substantia nigra in Parkinson disease. Ann Neurol 2012;71:267-277 https://doi.org/10.1002/ana.22592
  29. Lotfipour AK, Wharton S, Schwarz ST, Gontu V, Schafer A, Peters AM, et al. High resolution magnetic susceptibility mapping of the substantia nigra in Parkinson's disease. J Magn Reson Imaging 2012;35:48-55 https://doi.org/10.1002/jmri.22752
  30. Schwarz ST, Afzal M, Morgan PS, Bajaj N, Gowland PA, Auer DP. The ‘swallow tail' appearance of the healthy nigrosome - a new accurate test of Parkinson's disease: a case-control and retrospective cross-sectional MRI study at 3T. PLoS One 2014;9:e93814 https://doi.org/10.1371/journal.pone.0093814
  31. Blazejewska AI, Schwarz ST, Pitiot A, Stephenson MC, Lowe J, Bajaj N, et al. Visualization of nigrosome 1 and its loss in PD: pathoanatomical correlation and in vivo 7 T MRI. Neurology 2013;81:534-540 https://doi.org/10.1212/WNL.0b013e31829e6fd2

Cited by

  1. Structural MR Imaging in the Diagnosis of Alzheimer's Disease and Other Neurodegenerative Dementia: Current Imaging Approach and Future Perspectives vol.17, pp.6, 2016, https://doi.org/10.3348/kjr.2016.17.6.827
  2. Parkinson's disease and atypical parkinsonism: the importance of magnetic resonance imaging as a potential biomarker vol.50, pp.4, 2017, https://doi.org/10.1590/0100-3984.2017.50.4e1
  3. Multielement concentration analysis of Swiss mice brains on experimental model of Alzheimer's disease induced by β‐amyloid oligomers vol.46, pp.5, 2017, https://doi.org/10.1002/xrs.2753
  4. Computational modeling and biomarker studies of pharmacological treatment of Alzheimer's disease vol.18, pp.1, 2016, https://doi.org/10.3892/mmr.2018.9044
  5. Neuromelanin detection by magnetic resonance imaging (MRI) and its promise as a biomarker for Parkinson’s disease vol.4, pp.None, 2016, https://doi.org/10.1038/s41531-018-0047-3
  6. Method for Quantitative Evaluation of the Substantia Nigra Using Phase-sensitive Inversion Recovery in 1.5 T Magnetic Resonance Imaging vol.76, pp.6, 2016, https://doi.org/10.6009/jjrt.2020_jsrt_76.6.563
  7. Quantitative T1 mapping of the substantia nigra using phase-sensitive inversion recovery sequence at 3.0-T: a healthy volunteer study vol.62, pp.2, 2016, https://doi.org/10.1177/0284185120920806
  8. Diagnostic performance of neuromelanin-sensitive magnetic resonance imaging for patients with Parkinson’s disease and factor analysis for its heterogeneity: a systematic review and meta-analysis vol.31, pp.3, 2016, https://doi.org/10.1007/s00330-020-07240-7
  9. Reliability and Reproducibility of Neuromelanin‐Sensitive Imaging of the Substantia Nigra: A Comparison of Three Different Sequences vol.53, pp.3, 2016, https://doi.org/10.1002/jmri.27384